{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-02T18:57:50.057083+00:00","company":{"ticker":"OSCR","cik":1568651,"company_name":"Oscar Health, Inc."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"executive_change","fact_key":"dbff2a1f63","cik":1568651,"ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2026-06-02T10:31:58+00:00","payload":{"action":"transitioned","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2026-06-01","interim":false,"role":"Co-Founder & Advisor to the CEO","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Mario Schlosser changed role as Co-Founder & Advisor to the CEO at Oscar Health, Inc..","evidence_excerpt":"Mr. Schlosser’s transition from President of Technology and Chief Technology Officer of the Company to Co-Founder & Advisor to the CEO.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001568651-26-000048","anchor_url":"https://secwatch.observer/filing/0001568651-26-000048#claim-dbff2a1f63","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000048/0001568651-26-000048-index.htm"},{"fact_type":"earnings_release","fact_key":"e975cf3358e239b859acb9d52ab55c085266c220","cik":1568651,"ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"$2.07","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$678,996","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$4,647,194"},"claim":"Oscar Health, Inc. reported first quarter ended March 31, 2026 results: revenue $4,647,194, net income $678,996, EPS $2.07. Guidance reaffirmed.","evidence_excerpt":"results press release dated February 10, 2026. First Quarter 2026 Financial Highlights Three Months Ended March 31, (in thousands, except percentages) 2026 2025 Total revenue $4,647,194 $3,046,263 Medical loss ratio (“MLR”) 70.5% 75.4% Selling, general, and administrative (“SG&A”) expense ratio 15.2% 15.8% Earnings from operations $704,085 $297,123 Net income","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001568651-26-000036","anchor_url":"https://secwatch.observer/filing/0001568651-26-000036#claim-e975cf3358e239b859acb9d52ab55c085266c220","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000036/0001568651-26-000036-index.htm"},{"fact_type":"debt_financing","fact_key":"1d2c9301f1cec561f2e15a55f6b3bd93cbed631e","cik":1568651,"ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2026-02-10T23:59:59+00:00","payload":{"counterparty":"JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto","effective_date":"2026-02-06","event":"incurrence","instrument_type":"revolving_credit","interest_rate_text":"Term SOFR plus a margin of 4.50% per annum, or the Alternate Base Rate plus a ma","item_codes_triggered":["2.03"],"maturity_text":"February 6, 2029","principal_text":"$475.0 million"},"claim":"Oscar Health, Inc. incurred revolving credit of $475.0 million with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto at Term SOFR plus a margin of 4.50% per annum, or the Alternate Base Rate plus a ma maturing February 6, 2029.","evidence_excerpt":"On February 6, 2026, Oscar Health, Inc. (the “Company”), entered into a $475.0 million secured three-year revolving credit facility (the “Revolving Credit Facility”), pursuant to a Credit Agreement (the “Credit Agreement”), by and among the Company, certain subsidiaries of the Company, as subsidiary guarantors, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001568651-26-000008","anchor_url":"https://secwatch.observer/filing/0001568651-26-000008#claim-1d2c9301f1cec561f2e15a55f6b3bd93cbed631e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000008/0001568651-26-000008-index.htm"},{"fact_type":"material_agreement","fact_key":"d91847d22dde1b9ecf301253c9d7604745366911","cik":1568651,"ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2026-02-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Credit Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto","effective_date":"2026-02-06","item_codes_triggered":["1.01"],"value_text":"$475.0 million"},"claim":"Oscar Health, Inc. entered into Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto valued at $475.0 million (effective 2026-02-06).","evidence_excerpt":"On February 6, 2026, Oscar Health, Inc. (the “Company”), entered into a $475.0 million secured three-year revolving credit facility (the “Revolving Credit Facility”), pursuant to a Credit Agreement (the “Credit Agreement”), by and among the Company, certain subsidiaries of the Company, as subsidiary guarantors, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001568651-26-000008","anchor_url":"https://secwatch.observer/filing/0001568651-26-000008#claim-d91847d22dde1b9ecf301253c9d7604745366911","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000008/0001568651-26-000008-index.htm"},{"fact_type":"executive_change","fact_key":"eae6068243","cik":1568651,"ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2025-02-04T23:59:59+00:00","payload":{"action":"cease serving","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-24","interim":false,"role":"EVP, Chief Insurance Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Alessandrea Quane departed as EVP, Chief Insurance Officer at Oscar Health, Inc..","evidence_excerpt":"Alessandrea Quane, the Company’s EVP, Chief Insurance Officer, will cease serving in this role effective as of February 24, 2025 and her employment with the Company and Oscar Management Corporation (“OMC”) will terminate effective as of March 3, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001568651-25-000005","anchor_url":"https://secwatch.observer/filing/0001568651-25-000005#claim-eae6068243","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865125000005/0001568651-25-000005-index.htm"},{"fact_type":"executive_change","fact_key":"c77d6e4c8f","cik":1568651,"ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2025-02-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-05","interim":false,"role":"EVP and Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Steven Wolin resigned as EVP and Chief Operating Officer at Oscar Health, Inc..","evidence_excerpt":"Steven Wolin resigned as EVP and Chief Operating Officer of the Company, effective as of February 5, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001568651-25-000005","anchor_url":"https://secwatch.observer/filing/0001568651-25-000005#claim-c77d6e4c8f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865125000005/0001568651-25-000005-index.htm"},{"fact_type":"executive_change","fact_key":"159f995829","cik":1568651,"ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2025-02-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-24","interim":false,"role":"EVP and President of Oscar Insurance","role_category":"president","successor_name":null,"successor_named":false},"claim":"Janet Liang was appointed as EVP and President of Oscar Insurance at Oscar Health, Inc..","evidence_excerpt":"appointed Janet Liang as EVP and President of Oscar Insurance, effective February 24, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001568651-25-000005","anchor_url":"https://secwatch.observer/filing/0001568651-25-000005#claim-159f995829","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865125000005/0001568651-25-000005-index.htm"},{"fact_type":"earnings_release","fact_key":"f829e502171c1e03ccee401a83b950e963cc7c10","cik":1568651,"ticker":"OSCR","company_name":"Oscar Health, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":"$0.62","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$177.4 million","period_text":"First Quarter 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$2.1 billion"},"claim":"Oscar Health, Inc. reported First Quarter 2024 results: revenue $2.1 billion, net income $177.4 million, EPS $0.62. Guidance reaffirmed.","evidence_excerpt":"Oscar Health, Inc. ir.hioscar.com News Release Oscar Health Announces Results for First Quarter 2024 May 7, 2024 • For the quarter ended March 31, 2024: ◦ Total Revenue of $2.1 billion, a 46% increase YoY ◦ Medical Loss Ratio of 74.2%, a 210 bps improvement YoY ◦ SG&A Expense Ratio of 18.4%, an 870 bps improvement YoY ◦ Net Income attributable to Oscar of $177.4 million, or $0.62 of diluted earnings per share, a $217.1 million improvement YoY","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001568651-24-000013","anchor_url":"https://secwatch.observer/filing/0001568651-24-000013#claim-f829e502171c1e03ccee401a83b950e963cc7c10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865124000013/0001568651-24-000013-index.htm"}]}